According to the research report titled ‘Global Transcatheter Pulmonary Valve Replacement (TPVR) Market a?? Analysis By Application Type, By End User, By Region, By Country (2020 Edition): Market Insights, Competition and Forecast (2020-2025)’, available with Market Study Report, global transcatheter pulmonary valve replacement market had accounted for USD 287.6 million in 2019 and is expected to generate lucrative revenues by 2025.
 

Technological breakthroughs and growing popularity of valve replacement solutions coupled with increased pervasiveness of cardiovascular disorders are key factors fueling global transcatheter pulmonary valve replacement market. Currently only three products of TPVR have been approved by the FDA, with various other at the clinical stages.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2752224/
 

Key participants have also been focusing on expanding their product portfolio as well as their geographical reach. In addition, beneficial attributes such as easy installation and improved patient outcome in tandem with shifting preferences towards minimally invasive procedures are also stimulating the industry outlook.
 

In terms of value, the report states that pulmonary regurgitation segment is predicted to expand substantially over the study period. Growing demand for minimally invasive procedures and collective inclination towards using TPVR over SAVR are fueling the segmental share.
 

Global transcatheter pulmonary valve replacement industry size from hospitals and ambulatory surgical centers is expected to showcase significant expansion in the ensuing years. Surging investment towards R&RD activities, improving economic conditions, and high occurrence of valvular diseases are favoring the overall market scenario.
 

Considering the regional outlook, Europe is likely to account for the largest market share in the ensuing years, followed by North America and Asia-Pacific respectively. Factors such as widespread adoption of minimally invasive procedures, stabilizing economic conditions, and rising prevalence of pulmonary stenosis as well as pulmonary regurgitation are facilitating the business scenario in Europe.
 

The competitive landscape of global transcatheter pulmonary valve replacement industry is defined by companies such as Edwards Lifesciences, Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, and Venus MedTech HangZhou Inc. among others.